ARNA — Stock Film
STOCK FILMSCENE 1/11ARNA · $99.99
Stock Expert AI presents
ARNA
Arena Pharmaceuticals, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Arena Pharmaceuticals, Inc. A quick introduction.

On the stock market since 2000, it operates in the world of health and science. It has 448 employees. Now — the numbers.

on the stock market since 2000
448 employees
$0 market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $11493.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 78% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$21.3M
2017
$18M
2018
$806.4M
2019
$319K
2020
$54K
2021
In the vault right now:
$0
DEBT: $41.2M
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
4 / 8
EXPECTATIONS MET OR BEATEN
4
May 2020
Aug 2020
Nov 2020
Feb 2021
May 2021
Aug 2021
Nov 2021
Feb 2022
4 TIMES IN THE LAST 8 QUARTERS
A mixed scorecard.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Costs eat into the margin4/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

THE BRIGHT SIDE

Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $620.6M against $54K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, ARNA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: ARNA is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film